KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema

KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema

PURPOSE: To report the 100-week outcomes from the KESTREL and KITE trials. DESIGN: Two phase 3, double-masked, active-controlled, randomized trials. METHODS: Patients with diabetic macular edema (DME) were randomized 1:1:1 to brolucizumab 3 mg/6 mg (BRO3/BRO6) or aflibercept 2 mg (AFL) in KESTREL (N...

Full description

Bibliographic Details
Main Authors: Wykoff, Charles C., Garweg, Justus G., Regillo, Carl, Souied, Eric, Wolf, Sebastian, Dhoot, Dilsher S., Agostini, Hansjuergen T., Chang, Andrew, Laude, Augustinus, Wachtlin, Joachim, Kovacic, Lidija, Wang, Lixin, Wang, Ying, Bouillaud, Emmanuel, Brown, David M.
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2024
Subjects:
Medicine, Health and Life Sciences
Brolucizumab
Macular edema
Online Access:https://hdl.handle.net/10356/180077

Internet

https://hdl.handle.net/10356/180077

Similar Items